- Home
- MESO vs NWBI Comparison
MESO vs NWBI Comparison
Compare MESO & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MESO | NWBI |
|---|---|---|
| Founded | 2004 | 1896 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2005 | 2009 |
Fundamental Metrics
Financial Performance| Metric | MESO | NWBI |
|---|---|---|
| Price | $16.47 | $15.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 180.2K | ★ 714.1K |
| Earning Date | 02-26-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 5.82% |
| EPS Growth | N/A | ★ 16.46 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | N/A |
| Revenue This Year | $629.74 | $6.29 |
| Revenue Next Year | $30.65 | $5.06 |
| P/E Ratio | ★ N/A | $22.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.05 | $11.25 |
| 52 Week High | $21.50 | $16.16 |
Technical Indicators
Market Signals| Indicator | MESO | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 54.37 |
| Support Level | $15.37 | $15.37 |
| Resistance Level | $17.10 | $15.81 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 1.06 | 75.82 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.